17
5.1. Patients at Risk for HF (Stage A: Primary Prevention)
COR LOE
Recommendations
1 A 1. In patients with hypertension, blood pressure should be
controlled in accordance with GDMT for hypertension to
prevent symptomatic HF.
1 A 2. In patients with type 2 diabetes and either established CVD
or at high cardiovascular risk, SGLT2i should be used to
prevent hospitalizations for HF.
1 B-NR 3. In the general population, healthy lifestyle habits such as
regular physical activity, maintaining normal weight, healthy
dietary patterns, and avoiding smoking are helpful to reduce
future risk of HF.
2a B-R 4. For patients at risk of developing HF, natriuretic peptide
biomarker–based screening followed by team-based care,
including a cardiovascular specialist optimizing GDMT,
can be useful to prevent the development of LV dysfunction
(systolic or diastolic) or new-onset HF.
2a B-NR 5. In the general population, validated multivariable risk scores
can be useful to estimate subsequent risk of incident HF.
5. Stage A (Patients at Risk for HF)
